O
CLLS

OrbiMed’s Cellectis CLLS Stock Holding History

OrbiMed’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66,799
Closed -$1.73M – 146
2017
Q2 		$1.73M Sell
66,799
-283,201
-81% -$6.76M 0.02% 129
2017
Q1 		$8.4M Hold
350,000
– – 0.1% 102
2016
Q4 		$5.93M Hold
350,000
– – 0.08% 108
2016
Q3 		$8.43M Hold
350,000
– – 0.1% 105
2016
Q2 		$9.31M Hold
350,000
– – 0.1% 95
2016
Q1 		$9.63M Hold
350,000
– – 0.1% 96
2015
Q4 		$10.9M Hold
350,000
– – 0.1% 90
2015
Q3 		$9.23M Hold
350,000
– – 0.09% 94
2015
Q2 		$12.6M Buy
350,000
+50,000
+17% +$1.76M 0.11% 97
2015
Q1 		$10.4M Buy
+300,000
New +$10.9M 0.09% 101

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

OrbiMed's CLLS Position: Q3 2017 in Review

OrbiMed sold out of Cellectis (CLLS) in Q3 2017, closing a stake of 66,799 shares — an estimated $1.73M sold.

OrbiMed first reported a position in CLLS in Q1 2015 and held it in 10 quarters. The position peaked at $12.6M in Q2 2015. 42 funds tracked by Wall St. Rank hold CLLS as of Q3 2017.

  • OrbiMed reported no remaining Cellectis position as of Q3 2017 after selling out during the quarter.
  • OrbiMed sold 66,799 Cellectis shares in Q3 2017, an estimated $1.73M.
  • OrbiMed first reported a position in Cellectis in Q1 2015 and held it in 10 quarters.
  • OrbiMed's Cellectis position peaked at $12.6M in Q2 2015.
  • 42 funds tracked by Wall St. Rank held Cellectis as of Q3 2017.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.